Clinical trials: Upper Limb Spasticity
- Condition Upper Limb Spasticity
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Upper Limb Spasticity
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to…
- Trial name
- DIRECTION (NCT04936542)
- Testing
- AboBoNT-A, OnaBoNT-A
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 464 people
- Sponsor
- Ipsen
Spasticity, Post-Stroke
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.
- Trial name
- NCT01205451
- Testing
- Botulinum toxin type A
- Where
- 13 sites in China
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
- Conditions
- Stroke, Muscle Spasticity, Motor Neuron Disease
- Trial name
- NCT00076687
- Testing
- botulinum toxin Type A, saline
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 155 people
- Sponsor
- Allergan
Spasticity, Cerebrovascular Accident
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension…
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury
- Trial name
- NCT04815967
- Testing
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 32 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
The purpose of this study is to determine whether injections with increasing doses (up to 800 units) of Botulinum toxin type A into muscles of the leg and/or arm are safe and effective in treating patients with spasticity on one…
- Trial name
- NCT01603459
- Testing
- IncobotulinumtoxinA
- Where
- 33 sites in United States, Canada and 6 more
- Volunteers
- 155 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).
- Trial name
- NT-Spin (NCT00465738)
- Testing
- incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins")
- Where
- 27 sites in Austria, France and 6 more
- Volunteers
- 216 people
- Sponsor
- Merz Pharmaceuticals GmbH
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle…
- Trial name
- NCT01905683
- Testing
- IncobotulinumtoxinA (16-20 Units per kg body weight)
- Where
- 43 sites in Austria, Czechia and 10 more
- Volunteers
- 370 people
- Sponsor
- Merz Pharmaceuticals GmbH
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Cerebral Palsy, Spasticity
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating…
- Trial name
- XARA (NCT02002884)
- Testing
- IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
- Where
- 32 sites in United States, Argentina and 4 more
- Volunteers
- 351 people
- Sponsor
- Merz Pharmaceuticals GmbH
Spasticity
MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
This study is a randomized, double blind, multi-center, active drug controlled, phase III clinical trial to compare the efficacy and safety of MEDITOXIN® versus BOTOX® in treatment of post stroke upper limb(wrist, finger, thumb)…
- Trial name
- NCT01313767
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Medy-Tox
Muscle Spasticity
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
This is a prospective, non-interventional, observational study to collect data on the use of botulinum toxin Type A in a routine setting in patients with upper limb adult spasticity.
- Trial name
- NCT01387074
- Testing
- botulinum toxin Type A
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergan
Upper Limb Spasticity
Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
A proof of concept study to evaluate the feasibility of safe and effective treatment of upper limb spasticity using the Cryo-Touch III Device.
- Trial name
- NCT01863901
- Testing
- Treatment with Cryo-Touch III device
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Stroke, Hemiparesis
Fully Remote Use of IpsiHand Device in Hemiparetic Stroke
BCI-REHAB was a randomized clinical trial comparing an at-home brain-computer interface therapy system versus an at-home exercise program for upper-extremity rehabilitation in the chronic phases of stroke.
- Conditions
- Stroke, Hemiparesis, Spasticity as Sequela of Stroke, Brain Computer Interface
- Trial name
- NCT05965713
- Testing
- Neurolutions IpsiHand Upper Extremity Rehabilitation System, Home Exercise rehabilitation regimen Program (HEP)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Neurolutions, Inc.
Upper Limb Spasticity
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After…
- Trial name
- JUNIPER (NCT03821402)
- Testing
- DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U
- Where
- 26 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revance Therapeutics, Inc.
Spastic Hemiparesis
Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)
The purpose of this clinical study is to assess whether AbobotulinumtoxinA (Dysport®) injections in upper and lower limbs accompanied with a personal exercise plan called "Guided Self-rehabilitation Contract" (GSC) can improve…
- Trial name
- ENGAGE (NCT02969356)
- Testing
- Botulinum toxin type A, GSC
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 157 people
- Sponsor
- Ipsen
Muscle Spasticity, Stroke
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
- Trial name
- NCT02145676
- Testing
- onabotulinumtoxinA
- Where
- 2 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Allergan
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Post-stroke Spasticity of the Upper Limb
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.
- Trial name
- PURE (NCT01392300)
- Testing
- IncobotulinumtoxinA (400 Units)
- Where
- 47 sites in United States, Czechia and 5 more
- Volunteers
- 317 people
- Sponsor
- Merz Pharmaceuticals GmbH
Post-stroke Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin.
- Trial name
- NCT00432666
- Testing
- IncobotulinumtoxinA (Xeomin)
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 148 people
- Sponsor
- Merz Pharmaceuticals GmbH